Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bactecal Plus
- Development stage
- Unknown
- Lead developer
- Astel Medica
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bactecal Plus is a natural dietary supplement developed by Astel Medica to optimize intestinal function and support gut microbiota balance. It is formulated as an oral capsule containing 30 billion live bacteria from five specific strains across three families: *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, *Bifidobacterium infantis*, *Bifidobacterium lactis*, and *Streptococcus thermophilus*. Additionally, the supplement includes Vitamin A, which contributes to the maintenance of normal mucous membranes, such as the intestinal lining. The product is lactose-free, gluten-free, and suitable for use by pregnant or breastfeeding women. It is marketed as a nutraceutical intended for digestive health rather than a pharmaceutical drug in clinical development.
- Brand names
- Bactecal Plus
- Other names
- Bactecal® PLUS
02
Targets
RAR (Retinoic acid receptor)
Beyond the preview
Go deeper on Bactecal Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bactecal Plus.